Premium
Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis
Author(s) -
Stinco G.,
Piccirillo F.,
Patrone P.
Publication year - 2007
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2007.08188.x
Subject(s) - medicine , dermatology , adalimumab , psoriatic arthritis , psoriasis , family medicine , disease
A 39-year-old man with a 1-year history of psoriatic arthritis was treated with\udadalimumab 40 mg every 2 weeks subcutaneously. After 8 weeks of treatment\udthe patient developed hypercholesterolaemia\ud(267 mg/dL), hypertriglyceridaemia\ud(449 mg/)and weakness; we\uddecided to continue treatment and after 3 months of therapy\udthe patient developed a severe weakness and a remarkable hypertriglyceridaemia\ud(689 mg/dL) while total serum cholesterol\udlevels remained unchanged (264 mg/dL). Because of\udthese important alterations we decided to discontinue therapy\udwith the biological drug and after 4 weeks the TG level was\ud220 mg/dL), cholesterol level was 224 mg/dL) and weakness\udwas notably improved